Membership
Current Areas of Focus:
-
The Dosing Project™ – Establishing evidence-based dosing for Cannabis flower and products derived from analyses of crowd sourced patient responses
-
Chemotype-based Cultivar Selection for Health & Disease - Determining which plant strains work with which medical diagnosis
-
Sampling Guidelines for Product Analyses - Recommendations on how to sample cannabis plant and products for quality assurance
-
Formulation Guidelines for Processed Product Development - Consultations on how to best create your cannabis product
Who should join?
Cannabis Growers & Processors:
Benefit from information reported in all of the above focus areas
Cannabis Health Care Providers & Patients:
Benefit from information reported in 1 and 2 of the above focus areas


Complete the Membership Form below and take a step toward science based medical cannabis products
-
Become a General Member: ($500 per year)
-
Receive reports on Cannabis product cultivation, manufacturing and medical efficacy.
-
Receive access to CESC general research results and conclusions 90 days prior to general publication.
-
Receive one hour orientation and yearly consultation with CESC Chief Scientific Officer, Chief Medical Officer and Political Science expert.
-
-
Become a Sponsoring Member: ($5000 per year)
-
Sponsor research and development for specific products
-
Receive reports detailing results and conclusions for your specific product [Discounted T&M consultation rates will be applied]
-
CESC coordinate clinical research organization and product distribution for study with MediCann
-
Study conclusions will be submitted to peer reviewed publications
-
-
All members benefit from:
-
Webinars, Symposia and Conferences –produced by The CESC
-
Sponsorship recognition on our website
-
Social Media access linked to The CESC
-


Contact the CESC for more information

Planned Release Schedule of CESC Quarterly Reports for 2017
-
End 1Q 2017: Cannabis Flower Sampling Recommendations Derived from Analyses of Cannabinoid and Terpenoid Variance in Test Plots
-
End 2Q 2017: A Simplified Chemotyping Scheme for Optimal Medical Cannabis Strain Selection
-
End 3Q 2017: Further Insights into the Patient Medical Cannabis Evaluation
-
End 4Q 2017: Preliminary Conclusions from the Launch of The Dosing Project™